Irene M Shui1,2, Suzanne Kolb1, Christi Hanson1, Siobhan Sutcliffe3, Jennifer R Rider2,4, Janet L Stanford1,5. 1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 2. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts. 3. Division of Public Health Sciences and the Alvin J Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. 4. Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts. 5. Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington.
Abstract
BACKGROUND: The epidemiologic evidence for an association of Trichomonas vaginalis (Tv) with overall prostate cancer is mixed, but some studies suggest Tv may increase risk of more aggressive disease. The aim of this study was to assess whether Tv serostatus is associated with advanced or fatal prostate cancer. METHODS: A total of 146 men with advanced (metastatic or fatal) prostate cancer and 181 age-matched controls were selected from two prior population-based, case-control studies. Tv serostatus was determined with the same laboratory methods used in previous epidemiologic studies. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multivariable logistic regression to compare Tv serostatus in prostate cancer cases and controls adjusted for potential confounders. RESULTS: The seroprevalence of Tv in controls was 23%. Tv serostatus was not associated with an increased risk of metastatic or fatal prostate cancer (ORs < 1). CONCLUSIONS: Our study does not support an increased risk of advanced or fatal prostate cancer in men seropositive for Tv.
BACKGROUND: The epidemiologic evidence for an association of Trichomonas vaginalis (Tv) with overall prostate cancer is mixed, but some studies suggest Tv may increase risk of more aggressive disease. The aim of this study was to assess whether Tv serostatus is associated with advanced or fatal prostate cancer. METHODS: A total of 146 men with advanced (metastatic or fatal) prostate cancer and 181 age-matched controls were selected from two prior population-based, case-control studies. Tv serostatus was determined with the same laboratory methods used in previous epidemiologic studies. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multivariable logistic regression to compare Tv serostatus in prostate cancer cases and controls adjusted for potential confounders. RESULTS: The seroprevalence of Tv in controls was 23%. Tv serostatus was not associated with an increased risk of metastatic or fatal prostate cancer (ORs < 1). CONCLUSIONS: Our study does not support an increased risk of advanced or fatal prostate cancer in men seropositive for Tv.
Authors: Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford Journal: Am J Epidemiol Date: 2008-06-12 Impact factor: 4.897
Authors: Olivia Twu; Daniele Dessí; Anh Vu; Frances Mercer; Grant C Stevens; Natalia de Miguel; Paola Rappelli; Anna Rita Cocco; Robert T Clubb; Pier Luigi Fiori; Patricia J Johnson Journal: Proc Natl Acad Sci U S A Date: 2014-05-19 Impact factor: 11.205
Authors: Siobhan Sutcliffe; Edward Giovannucci; John F Alderete; Te-Hung Chang; Charlotte A Gaydos; Jonathan M Zenilman; Angelo M De Marzo; Walter C Willett; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-05 Impact factor: 4.254
Authors: Siobhan Sutcliffe; John F Alderete; Cathee Till; Phyllis J Goodman; Ann W Hsing; Jonathan M Zenilman; Angelo M De Marzo; Elizabeth A Platz Journal: Int J Cancer Date: 2009-05-01 Impact factor: 7.396
Authors: Jennifer R Stark; Gregory Judson; John F Alderete; Vasanthakrishna Mundodi; Ashwini S Kucknoor; Edward L Giovannucci; Elizabeth A Platz; Siobhan Sutcliffe; Katja Fall; Tobias Kurth; Jing Ma; Meir J Stampfer; Lorelei A Mucci Journal: J Natl Cancer Inst Date: 2009-09-09 Impact factor: 13.506
Authors: Miguelle Marous; Wen-Yi Huang; Charles S Rabkin; Richard B Hayes; John F Alderete; Bernard Rosner; Robert L Grubb; Anke C Winter; Siobhan Sutcliffe Journal: Cancer Causes Control Date: 2017-07-01 Impact factor: 2.506
Authors: Sabrina H Tsang; Samuel F Peisch; Brendan Rowan; Sarah C Markt; Amparo G Gonzalez-Feliciano; Siobhan Sutcliffe; Elizabeth A Platz; Lorelei A Mucci; Ericka M Ebot Journal: Int J Cancer Date: 2018-12-04 Impact factor: 7.396
Authors: Gareth D Westrop; Lijie Wang; Gavin J Blackburn; Tong Zhang; Liang Zheng; David G Watson; Graham H Coombs Journal: PLoS One Date: 2017-12-21 Impact factor: 3.240
Authors: Lanshan Huang; Melissa J LaBonte; Stephanie G Craig; Stephen P Finn; Emma H Allott Journal: Cancers (Basel) Date: 2022-03-08 Impact factor: 6.639